Evaluation of Trigeminal Ganglia Sensory Neuronal Population/s Mediating MIF-Induced Anti-Nociception in a Model of Apical Periodontitis.
根尖周炎模型中三叉神经节感觉神经元群介导 MIF 诱导的抗伤害感受的评估。
基本信息
- 批准号:10822712
- 负责人:
- 金额:$ 5.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-12-01 至 2027-11-30
- 项目状态:未结题
- 来源:
- 关键词:Absence of pain sensationAdvanced DevelopmentAdverse effectsAfferent NeuronsAftercareAnalgesicsAnimal ModelAntibodiesApicalAttenuatedBehavioral AssayBone ResorptionCXCR4 geneCapsaicinCellsChronicClinicalCoculture TechniquesDataDegenerative polyarthritisDental PulpDental Pulp ExposureDevelopmentDiagnosisDiseaseEnterobacteria phage P1 Cre recombinaseEvaluationFemaleFiberGenetic TranscriptionGoalsHypersensitivityImmunohistochemistryIn VitroInfectionInflammationInjectionsIntakeLeftMacrophageMaxillaMediatingMesenchymal Stem CellsMigraineModelingMusNeuronsNociceptionNociceptorsNon-Steroidal Anti-Inflammatory AgentsOpioidPainPatientsPeriapical GranulomaPeriapical PeriodontitisPeripheralPersistent painPharmaceutical PreparationsPhysical DependencePopulationPre-Clinical ModelPropertyPruritusPulp CanalsQuality of lifeRecombinantsReportingResearchReverse Transcriptase Polymerase Chain ReactionRiskScientistSortingStructure of trigeminal ganglionTRPV1 geneTestingTherapeuticTherapeutic EffectTooth structureToothacheTouch sensationTrainingTransgenic MiceWorkantinociceptioncareercentral sensitizationconditional knockoutconditioned place preferencecostcytokinedental infectionexperienceexperimental studyhuman RNA sequencinghuman stem cellsin vitro activityin vivoinsightintravenous injectionmalemechanical allodyniamouse Cre recombinasenovelorofacialpain reliefpainful neuropathypreventreceptorresponsespontaneous painstem cellssuccesstargeted treatmenttongue papilla
项目摘要
Abstract
Despite the success of root canal treatments at treating diseases such as apical periodontitis, 1.8 million patients
may experience persistent pain six months after treatment. Apical periodontitis is caused by an infection of the
dental pulp leading to mechanical allodynia and inflammation. Persistent dental pain increases cost of burden
and intake of analgesic drugs. Furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids provide
incomplete pain relief and adverse effects when taken chronically, highlighting the need for a novel treatment
that can provide relief to millions of patients experiencing persistent dental pain. The study of stem cells for their
analgesic properties has been rapidly growing in hopes of developing a novel class of analgesics. The efficacy
of mesenchymal stem cells has been demonstrated in pre-clinical models of neuropathic pain and in patients
diagnosed with migraines and osteoarthritis. Preliminary data demonstrates that intravenous injections of human
stem cells of the apical papilla (hSCAP) fully reverses hypersensitivity associated with apical periodontitis in
mice. RNA sequencing of hSCAP homed to the infected tooth shows a 133-fold increase in the expression of
the cytokine Macrophage Migratory Inhibitory Factor (MIF). Additionally, MIF receptors CD74 and CXCR4
colocalize on TRPV1+ neurons in the trigeminal ganglia. Moreover, a local injection of recombinant MIF reverses
hypersensitivity associated with apical periodontitis. Lastly, conditioned media from co-cultures of mouse
periapical granulomas (the infected tooth) and hSCAP attenuates capsaicin evoked Ca2+ response from
trigeminal ganglia neurons and is inhibited with pre-treatment of a MIF antibody. This data supports a novel
mechanism for stem cell anti-nociception through the direct effect of stem cells that is possibly mediated by MIF.
However, despite primary data suggesting MIF directly inhibits trigeminal ganglia neuronal activity, the neuronal
subtypes that MIF-induced anti-nociception are unknown. The pain induced by apical periodontitis is often
reported as referred, suggesting the involvement of non-nociceptive fibers due to central sensitization.
Understanding which of these subpopulations mediate MIF-induced anti-nociception will allow us to develop
targeted treatments for persistent dental pain associated with apical periodontitis. We will test the central
hypothesis that MIF-induced inhibition of trigeminal ganglia neuronal activity is mediated by nociceptive and non-
nociceptive neurons. To test this hypothesis, we will 1) conduct single cell RT-PCR and immunohistochemistry
to determine co-expression of MIF receptors CD74 and CXCR4 with different neuronal markers and 2) use Cre-
recombinase to conditionally knockout MIF receptors CD74 and CXCR4 from specific neuronal populations in
vivo and evaluate their contributions to MIF anti-nociception in a model of apical periodontitis. These studies will
not only provide novel insight into the neuronal populations that mediate MIF-induced anti-nociception but also
serve as an excellent training vehicle for my career as a clinician-scientist.
摘要
尽管根管治疗在治疗根尖周炎等疾病方面取得了成功,
可能会在治疗后六个月出现持续性疼痛。根尖牙周炎是由牙周组织感染引起的。
导致机械性异常性疼痛和炎症的牙髓。持续性牙痛增加负担成本
以及服用止痛药。此外,非甾体抗炎药(NSAID)和阿片类药物提供了
不完全的疼痛缓解和长期服用时的不良反应,突出了对新治疗的需求
可以缓解数百万持续牙痛的患者。干细胞的研究
镇痛剂的特性已经迅速发展,希望开发出一类新的镇痛剂。疗效
在神经性疼痛的临床前模型和患者中,
被诊断为偏头痛和骨关节炎初步数据表明,静脉注射人
根尖乳头干细胞(hSCAP)完全逆转与根尖牙周炎相关的超敏反应,
小鼠对感染牙齿的hSCAP的RNA测序显示,
巨噬细胞移动抑制因子(MIF)。此外,MIF受体CD 74和CXCR 4
共定位于三叉神经节中的TRPV 1+神经元上。此外,局部注射重组MIF可逆转
与根尖牙周炎相关的超敏反应。最后,将来自小鼠共培养物的条件培养基
根尖周肉芽肿(感染的牙齿)和hSCAP减弱辣椒素诱发的Ca 2+反应,
三叉神经节神经元,并且用MIF抗体的预处理抑制。这些数据支持了一种新的
通过可能由MIF介导的干细胞的直接作用的干细胞抗伤害感受的机制。
然而,尽管原始数据表明MIF直接抑制三叉神经节神经元的活动,但神经元的活动并不受影响。
MIF诱导的抗伤害感受的亚型是未知的。根尖周炎引起的疼痛通常
如所提及的那样报道,表明由于中枢致敏而涉及非伤害性感受纤维。
了解这些亚群中哪些介导了MIF诱导的抗伤害感受,将使我们能够开发
针对根尖周炎相关的持续性牙痛的治疗。我们将测试中央
假设MIF诱导的三叉神经节神经元活性抑制是由伤害性和非伤害性介导的,
伤害感受神经元为了验证这一假设,我们将1)进行单细胞RT-PCR和免疫组织化学
确定MIF受体CD 74和CXCR 4与不同神经元标记物的共表达,和2)使用Cre-
重组酶从特定的神经元群体中有条件地敲除MIF受体CD 74和CXCR 4,
在根尖牙周炎模型中评价它们对MIF抗伤害感受的贡献。这些研究将
不仅为介导MIF诱导的抗伤害感受的神经元群体提供了新的见解,
作为一个优秀的培训工具,我的职业生涯作为一个临床科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Josue De Jesus Murillo其他文献
Josue De Jesus Murillo的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
- 批准号:
10935820 - 财政年份:2023
- 资助金额:
$ 5.35万 - 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
- 批准号:
10932514 - 财政年份:2023
- 资助金额:
$ 5.35万 - 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
- 批准号:
10704845 - 财政年份:2023
- 资助金额:
$ 5.35万 - 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
- 批准号:
10709085 - 财政年份:2023
- 资助金额:
$ 5.35万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10409385 - 财政年份:2022
- 资助金额:
$ 5.35万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10710595 - 财政年份:2022
- 资助金额:
$ 5.35万 - 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
- 批准号:
10630975 - 财政年份:2022
- 资助金额:
$ 5.35万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
- 批准号:
10710588 - 财政年份:2022
- 资助金额:
$ 5.35万 - 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
- 批准号:
10788051 - 财政年份:2022
- 资助金额:
$ 5.35万 - 项目类别: